this study explored the effects of gnrh agonist (gnrha) immunity on expression of fshr mrna in pituitary and fshr protein in uteri, and also confirmed its efficacy on uterine development. 42 prepuberty and non cyclic ewes were assigned to 6 experimental groups (eg) during anestrus season. animals in eg-i, eg-ii and eg-iii were subcutaneously injected with 200, 300 and 400 μg alarelin antigens (...

results from 110 subjects with cpp, 46 girls (41.8%) were considered as intervention and 64 (58.2%) as control groups. the mean age at initial visit was 7.46 ± 1.03 years. the bmi standard deviation scores in both groups was not significantly different at sixth and 12th months of treatment compared with baseline (p = 0.257 and p = 0.839, respectively). the prevalence of obesity was not signific...

Background: The long protocol has been recognized as the gold standard in controlled ovarian hyperstimulation (COH). However, full dose of gonadotropin-releasing hormone agonist (GnRH-a) under prolonged become increasingly popular China. This study sought to compare pregnancy outcomes among following 3 groups: a group, and 2 types improved groups.

With the increasing use of gonadotropin releasing hormone antagonist protocols, it has become an option to trigger ovulation with gonadotropin releasing hormone agonist which has several advantages over human chorionic gonadotropin triggering; among those an elimination or reduction in ovarian hyperstimulation syndrome, and a reduction in luteal phase discomfort. Thus, this paper questions the ...

OBJECTIVE: The aim of this study is to evaluate the outcomes gonadotropin-releasing hormone agonist treatment for ovarian cysts, which are developed during tamoxifen use due breast cancer. STUDY DESIGN: This was a retrospective cohort including patients who were under stage I-III cancer and administered leuprolide acetate cysts with low malignancy risk between 2012-2020. RESULTS: Leuprolide tot...

To assess the effects of a gonadotropin-releasing hormone agonist, [D-Leu6,des-Gly10] luteinizing hormone-releasing hormone ethylamide, in ameliorating the damage caused by ionizing radiation, gonadotropin-releasing hormone agonist was administered to rats from day 22 to 37 of age in doses of 0.1, 0.4, and 1.0 microgram/day or vehicle and the rats were sacrificed on day 44 of age. There were no...

Human chorionic gonadotropin (hCG) is no longer a single, omnipotent ovulation triggering option. Gonadotropin releasing hormone (GnRH) agonist, initially presented as a substitute for hCG, has led to a new era of administering GnRH agonist followed by hCG triggering. According to this new concept, GnRH agonist enables successful ovum maturation, while hCG supports the luteal phase and pregnanc...

routinely, a bolus of 5.000-10.000 iu human chorionic gonadotropin (hcg) is usedfor the final follicular maturation and ovulation as a standard method. hcg has thesame effect of luteinizing hormone (lh) with long half-life. it has the longlutheotrophic effect which increases the risk of ovarian hyper stimulation syndrome(ohss). recently, gonadotropin-releasing hormone agonist (gnrh-a) trigger h...

Gonadotropin-releasing hormone (GnRH) agonist has been used in the treatment of a wide variety of sex-hormone-related diseases, as the administration of GnRH agonist can alter the secretion of gonadotropin and sex hormones. Recently, we found that the long-acting GnRH agonist aggravated hyperthyroidism and induced painless thyroiditis. This is the first report to demonstrate the association of ...